

Antineoplastic Therapy and Immunotherapy Course

This four-day course is designed to address the needs of the nursing and other oncology professionals in relation to antineoplastic and immunotherapies. It includes information on current and investigational pharmacotherapy, safe handling, administration of antineoplastic agents, and various issues concerning the management of patients receiving cancer therapy.

This course is NOT a certification course and is not intended to measure competency. Individual institutions are responsible for determining their own requirements for assessing clinical competency.

It is strongly recommended that attendees have taken the Foundations to Practice series prior to completing this course.

All courses are sponsored by UPMC Hillman Cancer Center.

The faculty consists of healthcare professionals with expertise in cancer care at UPMC.

Time and Location:

This course will be held virtually via Microsoft Teams. Exact class schedule will be provided in the confirmation letter sent via e-mail one week prior to the class. Electronic registration begins at 7:30 a.m. and lectures begin promptly at 8:00 a.m. The course concludes at approximately 4:30 p.m.

Who Should Attend:

The course is designed for nurses and other oncology professionals involved in cancer care. Six months of oncology experience and the completion of the Foundations to Practice Series (Pathophysiology of Cancer, Cancer Treatment Modalities, and the Immune System; Overview of Solid Tumors; Symptom Management of Patients with Cancer; Oncology Emergencies and Advanced Cancer Care Issues; and Hematological Malignancies) or other introductory cancer courses are *strongly recommended*.

Some course content is required for nurses working in Interventional Radiology (IR) at UPMC (only). Course registration must be done via HR Direct > Learning. Staff working in IR must enroll in Learning AND notify the course director at oconnorlj@upmc.edu to confirm registration for the IR appropriate lectures.

Continuing Education Credit:

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This certificate confirms that the participant has successfully completed the course and has the theoretical foundation needed to administer antineoplastic therapy and immunotherapy agents. This is not a certification course; individual institutions are responsible for

determining their own requirements based on internal policies for assessing clinical competency in chemotherapy and biotherapy administration.

Registration Information:

All UPMC employees are required to register for educational programs through Learning via HR Direct. A User Guide is available on the Infonet. Manager approval may be required for some programs for some employees. If you receive this notice when enrolling, please notify your manager of your interest in the program. Non-UPMC employees may register for the course by submitting a course registration form to the course director. Registration forms are located on the UPMC Hillman Cancer Center Professional Education Website <https://hillman.upmc.com/health-care-professionals/education/courses>

The registration fee for this course for virtual attendance is \$150. If combined with the entire Foundations to Practice Oncology Series, the cost for the virtual course is \$125. The registration fee includes program materials. Tuition is waived for employees of UPMC and UPMC affiliates.

Deadline for registration is one week before the course date.

Confirmation letters are emailed to all registrants one week prior to class. Confirmation email contains the following: Activity information sheet (agenda), course workbook, course homework, course study guide, course slide decks, registration link for CEU credit, as well as other details. If you have any questions, need more information, or do not receive confirmation prior to the course, contact Lynne O'Connor at oconnorlj@upmc.edu

Cancellation Policy:

- If you cannot attend any course day for any reason, you need to directly notify the course registrar by calling 412-623-3661 and leaving a voicemail message or by emailing Lynne O'Connor at oconnorlj@upmc.edu
- If Pittsburgh Public Schools are closed due to treacherous road conditions prior to 6 a.m., our courses are cancelled or will be offered virtually only. The course schedule is not changed by school delays.
- For any adverse weather conditions, please use your best judgment.
- For class cancellations, an announcement will be available at 412-623-3661 and an email will be sent to class attendees.

The program sponsors reserve the right to make changes or cancel the program because of unforeseen circumstances.

Personal Accommodations:

Please indicate any personal accommodations you may need for the program, such as sign language interpreter, large print conference materials, braille conference materials, wheelchair height tables, accessible parking, or other. Please call 412-623-3661 or email oconnorlj@upmc.edu two weeks prior to the program if you need any personal accommodations in order to participate.

Antineoplastic Therapy and Immunotherapy Course

Objectives

Upon completion of this course, participants will be able to:

- Compare and contrast the mechanism of action between antineoplastic therapy and immunotherapy.
- Recall the side effect profiles for the different classes of antineoplastic agents and immunotherapies.
- Recall nursing care considerations for patients receiving antineoplastic therapy and immunotherapy.
- Compare and contrast the mechanisms of action, side effect profile, complications, and management of side effects for patients receiving novel treatment modalities including CAR T-cell therapy, BiTE therapy, and TIL cell therapy.
- Describe the role that chemotherapy protectants play in the treatment of cancer.
- Recall patient barriers to adherence of oral cancer medications.
- Apply principles of antineoplastic therapy drug administration in calculating drug doses to include calculation of body surface area (BSA), absolute neutrophil count (ANC), creatinine clearance (Cr Cl) and carboplatin dosing.
- Describe the steps to ensure safe administration of antineoplastic and immunotherapy agents.
- Identify assessment priorities to effectively manage patient symptoms, dose-limiting toxicities, and adverse effects of antineoplastic therapy and immunotherapy.
- Recognize relevant resources for proper use of personal protective equipment (PPE) and excretion precautions.
- Prioritize the appropriate interventions for the management of hypersensitivity reactions.
- Describe the appropriate interventions for the management of vesicant extravasation.
- Discuss the differences between cancer genetics and cancer genomics.
- Identify the role that growth factors play when treating oncology patients.
- Recall strategies to prevent medication errors.

Course Content

- Alkylating Agents
- Antimetabolites
- Antineoplastic Therapy Administration
- Antitumor Antibiotics
- BiTE Therapy
- CAR T- Cell Therapy
- Case Study and Comprehensive Review
- Check Point Inhibitors
- Error Prevention
- Extravasation
- Genetics and Genomics
- Growth Factors
- Hormonal Therapies
- Hypersensitivity Reactions
- Interferon, Interleukin, L-Asparaginase, and Vaccine Therapy
- Miscellaneous Agents

- Monoclonal Antibodies
- Plant Alkaloids
- Principles of Cancer Drug Therapy
- Professional Resources
- Oral Adherence
- Organ Toxicities
- TIL Therapy
- Tyrosine Kinase Inhibitors